[Form 4] CUMBERLAND PHARMACEUTICALS INC Insider Trading Activity

Rhea-AI Filing Summary

Caroline Young, a director of Cumberland Pharmaceuticals Inc (CPIX), reported a sequence of open-market purchases of common stock executed under a Rule 10b5-1 trading plan adopted on November 14, 2024. Purchases occurred on multiple dates from 09/02/2025 through 09/30/2025, with reported per-share prices ranging from $3.05 to $3.60. After the final reported trade on 09/30/2025, the filing shows 33,030 shares beneficially owned by Ms. Young.

The transactions were automatic under the disclosed 10b5-1 plan; the filing is signed by an attorney-in-fact on behalf of Ms. Young and contains no derivative transactions or other compensatory awards. All information is limited to the trades listed and the plan adoption date disclosed in the explanation section.

Positive

• Director purchase activity under a Rule 10b5-1 plan shows transparent, preplanned accumulation
• Beneficial ownership increased to 33,030 shares by 09/30/2025

Negative

• None.

Insights

Corporate Governance Analyst

Director used an existing 10b5-1 plan to add ~1,084 shares in September 2025.

The filing documents a series of small, routine purchases executed automatically under a Rule 10b5-1 trading plan adopted on November 14, 2024. The final reported beneficial ownership is 33,030 shares, up incrementally across September trades.

This matters because 10b5-1 plans indicate pre‑arranged trading rather than opportunistic insider buys; the disclosure improves transparency about timing but does not by itself signal new material information about company operations.

Insider Transactions Specialist

Transactions are small-dollar, systematic purchases across 09/2025.

Reported per-share prices range from $3.05 to $3.60, showing consistent, low-cost accumulation rather than a single large block trade. No derivative activity is reported in Table II.

For investors, the filing is informational: it records insider accumulation under an established plan but contains no additional commitments, option exercises, or material changes to holdings beyond the share count disclosed.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Young Caroline

(Last) (First) (Middle)

1600 WEST END AVENUE

SUITE 1300

(Street)

NASHVILLE TN 37203

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CUMBERLAND PHARMACEUTICALS INC [ CPIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2025		L	V	4(1)	A	$3.54	32,946	D
Common Stock	09/03/2025		L	V	4(1)	A	$3.58	32,950	D
Common Stock	09/04/2025		L	V	4(1)	A	$3.6	32,954	D
Common Stock	09/05/2025		L	V	4(1)	A	$3.6	32,958	D
Common Stock	09/08/2025		L	V	4(1)	A	$3.41	32,962	D
Common Stock	09/09/2025		L	V	4(1)	A	$3.43	32,966	D
Common Stock	09/10/2025		L	V	4(1)	A	$3.39	32,970	D
Common Stock	09/11/2025		L	V	4(1)	A	$3.41	32,974	D
Common Stock	09/12/2025		L	V	4(1)	A	$3.54	32,978	D
Common Stock	09/15/2025		L	V	4(1)	A	$3.5	32,982	D
Common Stock	09/16/2025		L	V	4(1)	A	$3.5	32,986	D
Common Stock	09/17/2025		L	V	4(1)	A	$3.38	32,990	D
Common Stock	09/18/2025		L	V	4(1)	A	$3.31	32,994	D
Common Stock	09/19/2025		L	V	4(1)	A	$3.34	32,998	D
Common Stock	09/22/2025		L	V	4(1)	A	$3.29	33,002	D
Common Stock	09/23/2025		L	V	4(1)	A	$3.21	33,006	D
Common Stock	09/24/2025		L	V	4(1)	A	$3.1	33,010	D
Common Stock	09/25/2025		L	V	4(1)	A	$3.1	33,014	D
Common Stock	09/26/2025		L	V	4(1)	A	$3.05	33,018	D
Common Stock	09/29/2025		L	V	6(1)	A	$3.14	33,024	D
Common Stock	09/30/2025		L	V	6(1)	A	$3.12	33,030	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported purchase occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024.

Remarks:

	Caroline Young by /s/ John Hamm as attorney-in-fact	10/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What trades did the Cumberland Pharmaceuticals (CPIX) insider make in September 2025?

The filing reports multiple purchases of Common Stock from 09/02/2025 through 09/30/2025 at prices between $3.05 and $3.60.

Who filed the Form 4 for CPIX and what is their relationship to the company?

Caroline Young filed the Form 4 and is disclosed as a director of Cumberland Pharmaceuticals.

Were the September purchases made under a trading plan?

Yes. The purchases occurred automatically pursuant to a Rule 10b5-1 trading plan adopted on November 14, 2024.

How many shares did the reporting person beneficially own after the last reported trade?

The filing shows 33,030 shares beneficially owned following the reported transactions on 09/30/2025.

Did the Form 4 report any derivative transactions or option exercises?

No. Table II contains no derivative securities; only non-derivative common-stock purchases are reported.